ONCOLOGY Staff

Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.

Findings from the phase 3 MARIPOSA-2 trial were the subject of a recent discussion of ambivantamab plus chemotherapy with or without lazertinib in EGFR-mutated NSCLC.

Minimal residual disease as an end point in multiple myeloma has been widely discussed and was even a topic of a recent ODAC meeting.

Experts in multiple myeloma sat down to discuss the use of bispecific antibodies and their impact in the space.

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.

The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.

The conundrum of treating dermatologic adverse effects in response to treatment with amivantamab for EGFR-mutated NSCLC was discussed in a recent Frontline Forum.

A panel of experts in multiple myeloma discussed strategies for sequencing novel bispecific antibodies and CAR T-cell therapies for patients with relapsed/refractory disease.

Experts in multiple myeloma discussed the evolving role of CAR T-cell therapy for patients with relapsed/refractory disease.

Michael Wang, MD, spoke about the recent liso-cel approval in mantle cell lymphoma and the TRANSCEND trial.

Carey K. Anders, MD, spoke about updated findings in the HER2-positive breast cancer space, based on data from 2023 SABCS.

During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.

A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.

Advanced practice providers focus on the case of a patient diagnosed with multiple myeloma who lives in a rural area with limited access to care.

Hans Hammers, MD, and his team discuss the most pertinent treatment options for patients with renal cell carcinoma.

Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space following the 2023 ASH Annual Meeting and Exposition.

Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.

Jun Gong, MD, and Daneng Li, MD, discussed the most impactful trials coming from 2024 ASCO GI.

Experts in multiple myeloma debated the use of teclistamab through an inpatient or outpatient setting.

Narjust Florez, MD, and Sandip P. Patel, MD, cohosted a X chat centering on treatment options for KRAS G12C non–small cell lung cancer.

The CROWN and ADURA trials were discussed and defended as part of a non–small cell lung cancer Face Off.

Vanderbilt University Medical Center and Winship Cancer Institute at Emory University Face Off on recent data in multiple myeloma and acute lymphoblastic leukemia.

A group of experts discussed the approval process for teclistamab use in patients with multiple myeloma.

An overview of NRG1 fusion–positive tumors was given by experts in the gastrointestinal and lung cancer space in a recent Frontline Forum.

Ghayas C. Issa, MD, gave an all-encompassing review of current treatment options for acute myeloid leukemia and what to expect in the future.

Thomas Hutson, DO, PharmD, meets with his patient Cesar Fuentes to discuss his diagnosis and treatment for renal cell carcinoma.

A Satellite Session, involving members from US Oncology, focused on treatment options for patients with HER2-positive metastatic breast cancer.

During a Morning Rounds discussion, experts in the field of renal cell carcinoma reviewed treatment updates and the effective use of immunotherapy plus TKIs.

Kristen K. Ciombor, MD, MSCI, gives an overview of the current treatment landscape for patients with metastatic colorectal cancer.

Misako Nagasaka, MD, PhD, sheds light on neoadjuvant and adjuvant treatment options for patients with lung cancer.